Oral News and Research

RSS

Retina Implant AG presents clinical data of successful subretinal electronic implants

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of findings obtained during their first human clinical trial in the form of two oral presentations at The Eye and the Chip 2010 Annual Meeting in Detroit, Mich.

16 Sep 2010

Survey reveals physicians’ misperception on misuse, abuse of opioids

Findings from a new national survey, sponsored by the American Pain Foundation, reveal misperceptions among physicians regarding the misuse and abuse of opioids. The results come in light of government statistics to be released today looking at the broader U.S. population, showing 2009 rates of nonmedical use of these products nationwide.

16 Sep 2010

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.

16 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

Professor advocates steps to help health care industry increase patient understanding of health information

Studies show that nearly half of all Americans have difficulty understanding health information. Confusing medical directions, such as dosage and timing of prescription medicine, can lead to serious consequences including health setbacks, inappropriate hospital admissions and, sometimes, death. Now, researchers at the University of Missouri School of Health Professions are examining what health care facilities can do to increase patient understanding and positive outcomes.

16 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

16 Sep 2010

FDA updates dosing recommendation for Valcyte medication

The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant.

16 Sep 2010

Access Pharmaceuticals launches product website for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.

15 Sep 2010

Quick-Med receives patent for MultiStat technology to treat Rosacea

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,795,302 entitled "Use of Compositions for Treating Rosacea."

15 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

Oramed Pharmaceuticals announces clinical trial results of ORMD-0801 capsule in Type I diabetics

Oramed Pharmaceuticals Inc. announced today successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.

15 Sep 2010

SLActive chemical surfaces promote dental bone integration

Dental implants have offered a successful way to restore teeth for more than 20 years. New challenges for improving the process include shortening the time to restore functionality and meeting aesthetic demands. Altering implant surfaces to help promote bone integration is one solution. SLActive, a new chemically modified surface for titanium, the standard material of which implants are constructed, has shown positive results in this area.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

15 Sep 2010

Oral News and Research

Retina Implant AG presents clinical data of successful subretinal electronic implants

Survey reveals physicians’ misperception on misuse, abuse of opioids

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Professor advocates steps to help health care industry increase patient understanding of health information

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

FDA updates dosing recommendation for Valcyte medication

Access Pharmaceuticals launches product website for MuGard

Quick-Med receives patent for MultiStat technology to treat Rosacea

BioCryst reports results from forodesine studies for CTCL and CLL

Phase II clinical trial shows GTx-758 reduces serum free testosterone

COTI selected for Canadian life sciences partnering mission

Oramed Pharmaceuticals announces clinical trial results of ORMD-0801 capsule in Type I diabetics

SLActive chemical surfaces promote dental bone integration

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News